HTRS2025.P1.3 Abstract of Distinction Clinical Outcomes Over 3 Years of Once-Weekly Efanesoctocog Alfa Treatment in Adults and Adolescents from North America with Severe Hemophilia A in the Phase 3 XTEND-ed Long-Term Extension Study

Lignende værker

• HTRS2025.P1.3 Abstract of Distinction Clinical Outcomes Over 3 Years of Once-Weekly Efanesoctocog Alfa Treatment in Adults and Adolescents from North America with Severe Hemophilia A in the Phase 3 XTEND-ed Long-Term Extension Study
  af: Janice Staber, et al.
  Udgivet: (2025-11-01)
• HTRS2025.P2.62 Efanesoctocog alfa for successful immune tolerance induction in congenital hemophilia A with inhibitors
  af: Sanober Nusrat, et al.
  Udgivet: (2025-11-01)
• HTRS2025.P2.61 Post-operative outcomes in adult patients with Hemophilia A using efanesoctocog alfa
  af: Anya Parekh, et al.
  Udgivet: (2025-11-01)
• HTRS2025.P2.60 SYNOVIIIUS: Prospective Interventional Study of Effectiveness of Efanesoctocog Alfa Prophylaxis for Synovial Hypertrophy in Patients With Hemophilia A — Study Design
  af: Davide Matino, et al.
  Udgivet: (2025-11-01)
• Outcomes in participants switching from FVIII replacement therapy to efanesoctocog alfa prophylaxis in XTEND-1: a post hoc analysis
  af: Sophie Susen, et al.
  Udgivet: (2026-01-01)